Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.

Abstract: The invention provides compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER3 protein. Such compositions include epitopes of the HER3 protein.

Abstract: The present invention relates to a novel recombinant soluble human Tissue Factor(RshTF), which is an extrinsic hemostasis factor, produced in human HEK-cells. The present invention also relates to a hitherto unknown method of producing the RshTF as well as specific uses of RshTF and protein compositions comprising RshTF.

Abstract: Disclosed herein are polypeptides comprising an amino acid sequence of {[VPGVG]4IPGVG}n, wherein n is an integer greater than 1. The polypeptides can be crosslinked to from biocompatible hydrogels with tunable and desirable mechanical properties. The polypeptides and hydrogels can be used in a variety of biomedical applications including treatment of bleeding, treatment of soft tissue injury, injectable filler, and tissue adhesives.

Abstract: This disclosure relates to a novel Collagen Mimetic Peptide; a multi-arm conjugate comprising said peptide that mimics the higher order triple helical self-assembly of a collagen; a hydrogel comprising said Collagen Mimetic Peptide, optionally comprising collagen and optionally comprising a chemically modified surface; a corneal implant based on said hydrogel/modified hydrogel comprising a transparent central portion formed by an interpenetrating network comprising one or more additional biocompatible polymers wherein the central portion is adapted to remain cell free to ensure unhindered transmission of light.

Abstract: The invention is directed to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, a HIV fusion peptide inhibitor moiety and combinations thereof. More specifically, the present invention relates to polypeptides comprising a fibronectin-based scaffold domain protein that binds CD4, a fibronectin-based scaffold domain protein that binds the N17 domain of gp41, and a HIV fusion peptide inhibitor or combinations thereof. The invention also relates to the use of the innovative proteins in therapeutic applications to treat HIV.

Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Abstract: Apparatuses, compositions and methods for removing cells which interfere with regenerative processes. The apparatuses, compositions and methods selectively kill partially functional and/or non-functional cells versus functional cells while protecting functional proliferative cells to the extent that, upon removal of the killed cells by disintegration or scavenging, functional cells replace the partially- or non-functional cells.

Abstract: Methods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided. Such methods involve administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist or an activin receptor type 1 (ACVR1) antagonist. Antagonists include fusion proteins of one or more extracellular domains (ECDs) of ACVR2A, ACVR2B and/or ACVR1 and the Fc domain of an immunoglobulin heavy chain, and antibodies against ACVR2A, ACVR2B, ACVR1 or Activin A.

Abstract: Disclosed herein are methods of treating or reducing incidence of a cluster headache, e.g., chronic cluster headache and episodic cluster headache, and/or at least one secondary symptom associated with a cluster headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.

Abstract: The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an anti-fractalkine antibody, and a method for treating rheumatoid arthritis using the pharmaceutical composition, wherein the pharmaceutical composition and the method bring about therapeutically effective amelioration in rheumatoid arthritis after administration to a human subject. The present invention provides a pharmaceutical composition for the treatment of rheumatoid arthritis. The pharmaceutical composition in a method for treating rheumatoid arthritis comprises an anti-fractalkine antibody and a pharmaceutically acceptable excipient and is used such that at least 100 mg per dose of the anti-fractalkine antibody is subcutaneously administered to a human in need thereof.

Abstract: Provided is a method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction. Also provided are compositions including the agent.

Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.

Abstract: The invention provides methods and uses for stimulating, inducing, increasing or enhancing Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response, and an immune response by administering activin or a subsequence thereof, or an activator of activin receptor, in an amount effective to stimulate, induce, increase or enhance Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response, and an immune response, respectively. Also provided are peptides comprising or consisting of a subsequence of human activin sequence, in which the activin sequence or subsequence stimulates, induces, increases or enhances development of Tfh (follicular helper) cell differentiation, germinal center B cell development, an antibody response, an immune response and/or an immune response induced by a vaccine.

Abstract: The invention provides dual specific chimeric antigen receptors (CARs) having antigenic specificity for CD19 and CD22. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

Abstract: The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which X is a nucleic acid sequence which encodes a cleavage site; and A and B are nucleic acid sequences encoding a first and a second chimeric antigen receptor (CAR), each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens; wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain; and wherein: (a) the first and/or second CAR comprises an intracellular retention signal; and/or (b) the signal peptide of the first or second CAR comprises one or more mutation(s) such that it has fewer hydrophobic amino acids.

Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist.

Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD3, wherein said antibody or fragment thereof comprises a heavy chain variable domain comprising a CDR1 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. In addition, the present invention provides a method for polyclonal stimulation of T cells comprising contacting a population of T cells with said anti-CD3 antibody, optionally with an anti-CD28 antibody, wherein said anti-CD3 antibody and optionally said anti-CD28 antibody are linked to particles. Further said anti-CD3 antibody can be used for reversible tagging of cells.

Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16.

Abstract: Provided herein are, inter alia, methods of identifying agents that are capable inhibiting the binding (e.g., coupling) between a ROR1 protein and a ROR2 protein. By interfering with ROR1-ROR2 coupling (binding) the agents identified using the methods provided herein inhibit non-canonical Wnt5a signaling. Thus, the agents identified by the methods provided herein may, inter alia, be useful for cancer diagnosis and therapy.

Abstract: Provided herein are novel anti-LHR chimeric antigen receptor (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-LHR CAR, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-LHR antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting LHR.

Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.

Abstract: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.

Abstract: Compositions and methods are provided comprising soluble TRAIL polypeptide agents and cells engineered to express such agents for the treatment of multifocal brain metastases.

Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.

Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.

Abstract: Provided herein are methods and compositions for analyzing epigenetic modifications of genomes. The methods and compositions are suited for complete epigenome sequencing of any modification for which an antibody or an affinity binding agent has been developed. In one aspect, provided herein is a method for analyzing epigenetic modification of a genome. In some embodiments of aspects provided herein, the method further comprises sequencing a sequencing library to generate sequence reads, and assembling the sequence reads with aid of a positional barcode sequence information. In some embodiments of aspects provided herein, the method further comprises determining a location of at least two different epigenetic modifications of the nucleic acid. Another aspect of the present disclosure provides a kit for analyzing an epigenetic modification of a nucleic acid.

Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.

Abstract: A process for the oxidation of powder materials containing starch, which comprises the successive steps of mixing a powder material comprising starch with an aqueous solution of hydrogen peroxide (H2O2) and adding to the mixture thus obtained an aqueous solution of ammonia and reacting it with said mixture; the process may also comprise a further step of drying the aforementioned mixture to obtain a powder material containing oxidized starch; the process may advantageously comprise the steps of:—feeding a continuous flow of powder material containing starch into a first reactor (R) comprising a cylindrical tubular body (1) and a rotor, arranged in the cylindrical tubular body, comprising a shaft (8) provided with elements (9) projecting radially therefrom and rotated at a speed greater than or equal to 50 rpm,—feeding into said reactor also a continuous flow of an aqueous solution of hydrogen peroxide—reacting the powder material containing starch and the hydrogen peroxide;—discharging from a discharge openin

Abstract: The present invention provides a method capable of easily mixing any liquid containing a linking substance such as a divalent metal cation and the like with a liquid containing a particular compound at a high concentration, and capable of producing a liquid medium composition comprising fine structures dispersed therein, and a production device therefor and a kit therefor. The first liquid containing a particular compound is passed through a through-hole having a given cross-sectional area formed in a nozzle part at a given flow rate and injected into the second liquid at a given flow rate. By this simple operation, a structure in which the particular compound is bonded via the linking substance is formed, and the structure is preferably dispersed in a mixture of the both liquids.

Abstract: A composition comprising a compound mixture dissolved in water, the compound mixture comprising at least one chlorite salt at least one cyclodextrin; and at least one alkaline base; provided that the cyclodextrin is in an amount of 0.13 to 13 parts by mass for every 50 parts by mass of chlorite anion ClO2?, and the alkaline base is in an amount of up to 13 parts by mass for every 50 parts by mass of chlorite anion ClO2?; wherein the composition has a pH of at least 12.5. A process for forming the composition and process for treating suspensions of particles with the composition are also disclosed.

Abstract: The present invention relates to a polymerization initiator represented by Formula 1, a modified conjugated diene-based polymer, methods for preparing them, a rubber composition comprising the modified conjugated diene-based polymer, and a tire prepared from the rubber composition. (In Formula 1, the definition of each substituent is the same as defined in the description.

Abstract: A method for producing a halogenated isoolefin-based polymer includes irradiating an isoolefin-based polymer including alkylstyrene with light in presence of a halogen molecule. The isoolefin-based polymer has been polymerized by a living cationic polymerization using titanium chloride as a Lewis acid catalyst.

Abstract: Ethylene-based polymers comprising the following properties: (A) a density from 0.9190 g/cc to 0.9240 g/cc; (B) a hexane extractable level that is less than or equal to the lower of: (1) (A+(B*density (g/cc))+(C*log(MI) dg/min)) based on total weight of the ethylene-based polymer; where A=250.5 wt %, B=?270 wt %/(g/cc), C=0.25 wt %/[log(dg/min)], or (2) 2.0 wt %; (C) a G? (at G?=500 Pa, 170° C.) that meets the following equation: G??D+E[log (12)], where D=150 Pa and E=?60 Pa/[log(dg/min)]; and (D) a melt index (12) from 1.0 to 20 dg/min; are made in process comprising the step of contacting in a reaction configuration, comprising a first tubular reaction zone 1 and a last tubular reaction zone i, in which i is greater than or equal to (?) 3, under high pressure polymerization conditions, and in which the first reaction zone 1 has a peak polymerization temperature greater than the peak temperature of the ith reaction zone, and wherein the difference in these two peak temperatures is ?30° C.

Abstract: Embodiments of the disclosure generally provide compositions and methods related to articles that display reversible photoresponsive behavior.

Abstract: Disclosed are LEDs and LED packages, and methods of making them, having improved resistance to infiltration by chemical entities comprising providing a coating on at least a portion of the LED chip or an LED chip package formed by co-polymerization of: (a) one or more hydrofluoroolefin monomer(s) selected from the group consisting of tetrafluoroethylene, hydrofluoroethylenes, hydrofluoropropenes, hydrofluorobutenes, hydrofluoropentenes and combinations of these; (b) optionally one or more chlorofluoroethylene monomers; (c) optionally one or more vinyl ester monomer(s); and (d) optionally one or more vinyl ether monomer(s), wherein at least a portion of said vinyl ether monomer is preferably a hydroxyl group-containing vinyl ether monomer and preferably at least one of (b) and (d) is present.

Abstract: The present invention relates to copolymers of ethylene, vinyl esters of an akyl carboxylic acid and other specific unsaturated carboxylic esters which have lower glass transition temperature than copolymers of ethylene and vinyl esters of an alkyl carboxylic acid, and also to production and use of these, to vulcanizable mixtures comprising the copolymers of the invention, to crosslinking of these and to vulcanizates and mouldings obtainable therefrom.

Abstract: Acrylic copolymers that include the controlled placement of particular functional groups within the polymer structure are provided. The copolymers comprise a first reactive segment of including a functional group selected from the group consisting of a UV active functional group, a reactive functional group, a non-reactive functional group, and combinations thereof and a second segment including a functional group selected from the group consisting of a reactive functional group, a non-reactive functional group, and combinations thereof. The acrylic copolymers are manufactured via a controlled radical polymerization process. The copolymers are useful in the manufacture of adhesives and elastomers.

Abstract: Provided are a polymerizable composition in which precipitation or the like of crystals does not occur and which has high storage stability; and a polymerizable composition in which unevenness is unlikely to occur when a film-like polymerized material obtained by polymerizing the composition is prepared. Further, provided are an optically anisotropic body, a retardation film, an optical compensation film, an anti-reflective film, a lens, and a lens sheet which are formed of the polymerizable composition, a liquid crystal display element, an organic light-emitting display element, a lighting element, an optical component, a colorant, a security marking, a member for emitting a laser, a polarizing film, a coloring material, and a printed matter for which the polymerizable composition is used.

Abstract: The invention provides an acrylic block copolymer which has excellent transparency, profile extrusion properties and surface smoothness of shaped articles, and which is also excellent in light guiding properties. The acrylic block copolymer includes a polymer block (a1) predominantly containing methacrylic acid ester units and a polymer block (a2) predominantly containing acrylic acid ester units, and has a refractive index of 1.485 to 1.495 and an order-disorder transition temperature (ODTT) of not more than 260° C.

Abstract: A resin for ink is obtained by reaction of a lignin, phenols, aldehydes, a rosin-based resin, and polyhydric alcohol.